Keymed Biosciences Co.ltd

This study tests a new drug, CM518D1, in about 434 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely m…

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who already finished treatment in an earlier CM512 study. The main goal is to track any side effects over time.

This study tests a new drug called CM336 in adults whose AL amyloidosis has come back or not responded to prior treatment. AL amyloidosis is a rare disease where abnormal proteins build up in organs. The drug is a bispecific antibody designed to help the immune system attack the …

This study tests a new drug called CM336 for people with certain blood disorders (like low platelets or anemia) that have come back or not responded to other treatments. The drug works by helping the immune system stop attacking the body's own blood cells. About 158 adults will t…

This study tests an experimental drug called CM512 for people with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't go away with standard antihistamines. About 48 adults will receive either CM512 or a placebo injection. The main goal is to see if th…

This early-stage study tests a new drug, CM559, in 40 healthy men to see if it is safe and how the body handles it. Participants receive a single dose of the drug or a placebo. The study does not aim to treat any disease, but to gather important safety information for future rese…

This early-stage study tests a new drug, CM383, in 30 healthy men to see how the body absorbs and processes it, and to check for any safety issues. Participants receive a single dose either as an IV or a shot. The goal is to gather basic information, not to treat any disease.